Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Emberton

Showing results (21-30 of 474) with videos related to

Pageof 48
Sort By:
Nature Reviews. Clinical Oncology|May 14, 2014
Management of low risk prostate cancer-active surveillance and focal therapyLaurence Klotz, Mark Emberton
BJU International|June 25, 2009
Screening for prostate cancer appears to work, but at what cost?Chris Parker, Mark Emberton
Current Opinion in Urology|April 9, 2014
Management of low risk prostate cancer: active surveillance and focal therapyLaurence Klotz, Mark Emberton
International Journal of Surgery (London, England)|December 15, 2015
Evidence based management of male lower urinary tract symptoms: A contemporary updateVeeru Kasivisvanathan, Mark Emberton
The Journal of Urology|May 1, 2016
Editorial CommentHashim Ahmed, Mark Emberton
BJU International|September 13, 2005
Is it time to reconsider the role of prostatic inflammation in the pathogenesis of lower urinary tract symptoms?Jim Armitage, Mark Emberton
Current Opinion in Urology|December 20, 2007
The role of anticholinergic drugs in men with lower urinary tract symptomsJames Armitage, Mark Emberton
Current Opinion in Urology|November 6, 2009
Behaviour modification and benign prostatic hyperplasia: replacement for medicationsTet Yap, Mark Emberton
BJU International|June 21, 2005
Prolonging survival in prostate cancer: chemotherapy will have an important roleChris Parker, Mark Emberton
The Journal of Urology|September 11, 2017
Re: Magnetic Resonance Imaging Underestimation of Prostate Cancer Geometry: Use of Patient Specific Molds to Correlate Images with Whole Mount Pathology: A. Priester, S. Natarajan, P. Khoshnoodi, D. J. Margolis, S. S. Raman, R. E. Reiter, J. Huang, W. Grundfest and L. S. Marks J Urol 2017;197:320-326Clément Orczyk, Mark Emberton
Pageof 48

Showing results (21-30 of 474) with videos related to

Sort By:
Pageof 48
Nature Reviews. Clinical Oncology|May 14, 2014
Management of low risk prostate cancer-active surveillance and focal therapyLaurence Klotz, Mark Emberton
BJU International|June 25, 2009
Screening for prostate cancer appears to work, but at what cost?Chris Parker, Mark Emberton
Current Opinion in Urology|April 9, 2014
Management of low risk prostate cancer: active surveillance and focal therapyLaurence Klotz, Mark Emberton
International Journal of Surgery (London, England)|December 15, 2015
Evidence based management of male lower urinary tract symptoms: A contemporary updateVeeru Kasivisvanathan, Mark Emberton
The Journal of Urology|May 1, 2016
Editorial CommentHashim Ahmed, Mark Emberton
BJU International|September 13, 2005
Is it time to reconsider the role of prostatic inflammation in the pathogenesis of lower urinary tract symptoms?Jim Armitage, Mark Emberton
Current Opinion in Urology|December 20, 2007
The role of anticholinergic drugs in men with lower urinary tract symptomsJames Armitage, Mark Emberton
Current Opinion in Urology|November 6, 2009
Behaviour modification and benign prostatic hyperplasia: replacement for medicationsTet Yap, Mark Emberton
BJU International|June 21, 2005
Prolonging survival in prostate cancer: chemotherapy will have an important roleChris Parker, Mark Emberton
The Journal of Urology|September 11, 2017
Re: Magnetic Resonance Imaging Underestimation of Prostate Cancer Geometry: Use of Patient Specific Molds to Correlate Images with Whole Mount Pathology: A. Priester, S. Natarajan, P. Khoshnoodi, D. J. Margolis, S. S. Raman, R. E. Reiter, J. Huang, W. Grundfest and L. S. Marks J Urol 2017;197:320-326Clément Orczyk, Mark Emberton
Pageof 48